Trial
NCT02535364
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Juno Therapeutics, a Subsidiary of Celgene
Collaborators
—
Condition
Acute Lymphoblastic Leukemia
Intervention
JCAR015 (CD19-targeted CAR T cells)
Why stopped
Safety reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-05-04